Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT
Stereotactic body radiation therapy (SBRT) has emerged as one of the leading curative method for
early stage non-small cell lung cancer (NSCLC). However, assessing the status of the disease
during post-SBRT follow up presents a challenge. Currently, chest Computed Tomography (CT)
is the main technique to detect whether cancer has come back, but this method has
demonstrated poor accuracy and reliability in determining if the observed post-operative
lung changes are benign or malignant.
Positron-emission tomography (PET) is an imaging technique that uses special radioactive
tracers to cell growth. The use of PET scans with a tracer that target the pathways of DNA
synthesis may be more accurate than CT for detecting if the cancer has come or not.
The purpose of this study is to see if a PET radiotracer called 18F-FLT
(3'-deoxy-3'-fluorothymidine) can identify cancer recurrences accurately compared to regular
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society